Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 21;62(1):e01923-17.
doi: 10.1128/AAC.01923-17. Print 2018 Jan.

Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131

Ángel Rodríguez-Villodres  1 , José Manuel Ortiz de la Rosa  1 , Rocío Álvarez-Marín  1 , Jerónimo Pachón  1   2 , Javier Aznar  1   3 , José Antonio Lepe  1 , Younes Smani  4
Affiliations

Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131

Ángel Rodríguez-Villodres et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: Escherichia coli; ST131; heteroresistance; piperacillin-tazobactam.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Etests with piperacillin-tazobactam (TZP) of isolate C2-23 with a 0.5 McFarland standard inoculum (a) and isolate C1-140 with 0.5 (b) and 2 (c) McFarland standard inocula. Colonies growing in the inner inhibition zone are characteristic of heteroresistance.
FIG 2
FIG 2
PAP of isolates C2-23 and C1-140 when 0.5 and 2 McFarland standard inocula are used. MICs and NICs are shown. A MIC/NIC ratio of >8 defines the population as heteroresistant to the antibiotic, a MIC/NIC ratio of >2 and ≤8 defines it as intermediately heteroresistant, and a MIC/NIC ratio of ≤2 defines it as homogeneously resistant. O.D., optical density.
See this image and copyright information in PMC

References

    1. Pournaras S, Ikonomidis A, Neou E, Kantzanou M, Maniatis AN, Tsakris A. 2008. Piperacillin/tazobactam heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. J Antimicrob Chemother 61:757–758. doi:10.1093/jac/dkm528. - DOI - PubMed
    1. Ma W, Sun J, Yang S, Zhang L. 2016. Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China. Eur J Clin Microbiol Infect Dis 35:571–578. doi:10.1007/s10096-015-2572-x. - DOI - PubMed
    1. Sun JD, Huang SF, Yang SS, Pu SL, Zhang CM, Zhang LP. 2015. Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China. Clin Microbiol Infect 469:e1–e10. doi:10.1016/j.cmi.2014.12.013. - DOI - PubMed
    1. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 60:1136–1151. doi:10.1111/j.1365-2958.2006.05172.x. - DOI - PMC - PubMed
    1. Briñas L, Zarazaga M, Sáenz Y, Ruiz-Larrea F, Torres C. 2002. β-Lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother 46:3156–3163. doi:10.1128/AAC.46.10.3156-3163.2002. - DOI - PMC - PubMed

Publication types

MeSH terms